backgroundcommun
acquir
respiratori
viru
carv
infect
occur
frequent
lung
transplant
may
advers
impact
outcom
hypothes
asymptomat
carriag
would
increas
risk
chronic
lung
allograft
dysfunct
clad
graft
loss
sever
infect
would
methodsal
lung
transplant
case
januari
juli
perform
center
review
respiratori
viral
sampl
isol
viru
classifi
accord
clinic
level
sever
asymptomat
symptomat
without
pneumonia
viral
pneumonia
multivari
cox
model
employ
assess
impact
carv
isol
progress
clad
graft
loss
specimen
collect
total
patient
patient
produc
viru
posit
specimen
episod
carv
infect
overal
risk
clad
elev
viral
infect
hr
p
risk
howev
due
viral
pneumonia
alon
hr
p
without
signific
impact
symptomat
viral
infect
hr
p
asymptomat
viral
infect
hr
p
risk
graft
loss
chronic
lung
allograft
dysfunct
clad
commonli
bronchiol
obliteran
syndrom
bo
remain
lead
caus
morbid
mortal
lung
transplant
divers
group
infecti
noninfecti
posttranspl
event
associ
increas
risk
subsequ
clad
bacteri
viral
infect
howev
make
bulk
identifi
posttranspl
insult
introduct
respiratori
viru
multiplex
polymeras
chain
reaction
pcr
increas
detect
awar
commun
acquir
respiratori
virus
carv
yet
impact
carv
infect
lung
allograft
function
surviv
lung
transplant
well
defin
prior
studi
carv
infect
lung
transplant
come
vari
conclus
respect
carv
impact
clad
graft
surviv
viral
infect
may
indirectli
influenc
develop
clad
via
induct
acut
allograft
reject
recent
evid
argu
mechan
patient
carv
infect
progress
clad
clinic
predictor
progress
lack
sinc
carv
infect
rang
asymptomat
viral
carriag
fulmin
respiratori
failur
hypothes
allograft
outcom
influenc
infect
sever
specif
hypothes
carv
pneumonia
would
greater
impact
develop
clad
graft
loss
would
asymptomat
carv
carriag
widespread
adopt
highsensit
pcr
test
increasingli
identifi
presenc
viru
asymptomat
individu
precis
understand
impact
individu
virus
viru
sever
allograft
outcom
help
inform
clinic
decis
improv
outcom
reduc
cost
avoid
unnecessari
treatment
primari
object
studi
assess
impact
carv
infect
outcom
graft
loss
clad
onset
graft
loss
defin
patient
death
retransplant
clad
defin
accord
ishlt
guidelin
secondari
object
evalu
impact
individu
virus
outcom
graft
loss
clad
approv
ucla
institut
review
board
patient
underw
lung
transplant
univers
california
lo
angel
ucla
januari
juli
includ
studi
patient
prospect
enrol
observ
cohort
studi
outcom
lung
transplant
recipi
underw
routin
bronchoscopi
bronchoalveolar
lavag
bal
day
week
month
posttranspl
addit
bal
sputum
nasopharyng
sampl
obtain
provid
discret
swab
donor
bronchu
sent
bacteri
viral
organ
time
transplant
exclud
analysi
standard
care
lung
transplant
patient
includ
prophylaxi
immunosuppress
lung
function
measur
acut
cellular
reject
acr
treatment
describ
elsewher
acr
diagnos
accord
standard
ishlt
criteria
clad
identifi
follow
process
first
patient
less
pulmonari
function
test
pft
exclud
retranspl
patient
transplant
date
data
collect
second
transplant
exclud
infect
pleural
effus
caus
fev
declin
exclud
review
medic
record
per
ishlt
criteria
includ
patient
follow
requir
baselin
fev
measur
best
valu
date
measur
fvc
measur
time
baselin
measur
clad
ye
clad
defin
sustainedirrevers
declin
fev
baselin
use
averag
baselin
measur
sustain
declin
present
least
consecut
pft
never
improv
baselin
followup
next
clad
present
fev
fvc
measur
time
clad
onset
found
clad
phenotyp
onset
determin
use
follow
formula
valu
phenotyp
bo
phenotyp
ra
clad
phenotyp
time
last
pft
measur
also
determin
use
formula
specimen
posit
viru
postlung
transplant
patient
identifi
via
ucla
clinic
microbiolog
laboratori
databas
viral
infect
defin
posit
viral
test
bal
expector
sputum
tracheal
suction
nasopharyng
wash
isol
consid
distinct
episod
viru
isol
within
day
chang
associ
clinic
sever
grade
see
episod
pseudomona
aspergillu
similarli
defin
without
regard
clinic
sever
viral
detect
perform
ucla
clinic
microbiolog
laboratori
januari
octob
viral
identif
cultur
base
identifi
respiratori
syncyti
virus
b
influenza
parainfluenza
type
enteroviru
rhinoviru
adenoviru
sampl
setup
shell
vial
rmix
system
cultur
agmk
kidney
aveolar
epitheli
fibroblast
cell
cultur
held
week
octob
respiratori
viru
multiplex
pcr
panel
resplex
ii
ruo
qiagen
introduc
capabl
detect
differ
virus
respiratori
syncyti
virus
b
influenza
virus
b
parainfluenza
virus
type
human
metapneumoviru
coxsacki
echoviru
rhinoviru
adenoviru
serogroup
b
e
bocaviru
coronavirus
pcr
multiplex
panel
could
reliabl
distinguish
rhinoviru
enterovirus
thu
cultur
pcr
result
virus
combin
analysi
rhinovirusenteroviru
except
made
categori
call
coxsacki
echoviru
result
uniqu
resplex
ii
ruo
ie
contain
cultur
deriv
result
microbiolog
laboratori
qualiti
control
data
shown
found
major
virus
coxsackieechoviru
group
rhinoviru
outcom
analysi
found
group
behav
differ
rhinovirusenteroviru
group
thu
maintain
separ
viral
categori
outcom
analysi
cytomegaloviru
herp
simplex
viru
infect
exclud
analys
focu
commun
acquir
respiratori
virus
carv
infect
stratifi
base
level
clinic
sever
asymptomat
viral
infect
symptomat
viral
infect
viral
pneumonia
qualifi
symptom
symptomat
infect
includ
new
worsen
short
breath
hypoxemia
new
worsen
cough
fever
viral
pneumonia
defin
clinic
symptomat
viral
infect
plu
radiograph
infiltr
without
clear
altern
explan
therefor
differ
symptomat
viral
infect
viral
pneumonia
radiograph
infiltr
asymptomat
episod
meet
criteria
either
symptomat
viral
infect
viral
pneumonia
sever
level
determin
consensu
studi
team
pra
pi
alg
base
comprehens
chart
review
viral
episod
discrep
isol
difficult
case
isol
togeth
total
isol
independ
review
alg
patient
demograph
clinic
characterist
describ
frequenc
categor
variabl
mean
standard
deviat
sd
continu
variabl
addit
median
interquartil
rang
iqr
time
observ
incid
infect
comput
isol
sever
level
well
month
year
multivari
cox
proport
hazard
model
develop
covari
age
transplant
type
transplant
singl
doubl
prtransplant
diagnosi
transplant
era
time
interv
start
timedepend
pseudomona
aeruginosa
respiratori
isol
includ
colon
infect
timedepend
aspergillu
speci
respiratori
isol
includ
small
larg
conidia
timedepend
cumul
acut
reject
score
timedepend
clad
graft
loss
outcom
aspergillu
pseudomona
common
isol
previous
identifi
signific
risk
factor
subset
cohort
therefor
includ
model
minim
confound
timedepend
aspergillu
pseudomona
clad
patient
consid
unexpos
infect
condit
time
transplant
upon
first
infect
diagnosi
clad
consid
expos
remaind
observ
period
variabl
signific
p
level
univari
analys
includ
multivari
analys
cmv
reach
criteria
inclus
associ
viral
infect
outcom
clad
graft
loss
assess
use
timedepend
approach
measur
infect
patient
consid
unexpos
viral
infect
transplant
consid
viral
exposur
experienc
viral
infect
patient
consid
unexpos
viral
infect
transplant
categor
exposur
asymptomat
viral
infect
symptomat
viral
infect
viral
pneumonia
experi
episod
viral
infect
rang
sever
level
timedepend
construct
viral
infect
sever
patient
retain
highest
sever
level
experienc
date
univari
cox
proport
hazard
model
use
assess
associ
timedepend
exposur
viru
adenoviru
coronaviru
coxsackieechoviru
influenza
b
metapneumoviru
parainfluenza
rhinovirusenteroviru
rsv
outcom
clad
graft
loss
repeat
measur
mix
effect
model
incorpor
tacrolimu
valu
use
account
intrasubject
correl
among
observ
hazard
ratio
hr
report
correspond
confid
interv
ci
bracket
test
signific
statist
signific
pvalu
threshold
analys
conduct
use
sa
sa
institut
inc
cari
nc
usa
statist
signific
differ
baselin
characterist
found
without
viral
infect
tabl
clad
develop
patient
mean
sd
year
patient
experienc
graft
loss
mean
sd
year
total
cohort
patient
could
assess
clad
primarili
insuffici
number
pulmonari
function
test
requir
make
diagnosi
exclud
outcom
analysi
clad
overal
transplant
outcom
contrast
without
viral
infect
shown
tabl
total
specimen
collect
patient
patient
viral
infect
studi
period
specimen
posit
viru
separ
episod
viral
infect
mean
sd
year
transplant
asymptomat
infect
symptomat
infect
episod
clinic
pneumonia
posit
specimen
bal
sampl
sputum
nasal
wash
tracheal
aspir
specimen
posit
viru
simultan
fortyon
patient
viral
episod
viral
infect
episod
coxsackieechoviru
group
includ
rhinovirus
account
greatest
number
follow
rhinoviru
enteroviru
parainfluenza
coronaviru
rsv
human
metapneumoviru
influenza
adenoviru
influenza
b
bocaviru
distribut
infect
viru
clinic
sever
level
shown
figur
viral
infect
occur
often
januari
februari
march
juli
august
septemb
fewest
infect
figur
cohort
fourteen
pulmonari
bacteri
isol
identifi
within
thirti
day
follow
viral
infect
preclud
analysi
condit
uniqu
covari
episod
pulmonari
pseudomona
aeruginosa
patient
episod
respiratori
aspergillu
patient
risk
clad
elev
carv
infect
clinic
sever
analyz
group
hr
respiratori
viru
pcr
panel
introduc
octob
greatli
increas
test
sensit
picornavirus
coronaviru
metapneumoviru
identifi
cultur
method
interestingli
new
test
modal
influenc
outcom
clad
graft
loss
also
effect
either
clad
graft
loss
era
transplant
level
immunosuppress
time
carv
assess
use
tacrolimu
trough
blood
level
proxi
found
median
tacrolimu
level
overal
cohort
lower
mcgl
time
viral
infect
median
level
time
asymptomat
mcgl
symptomat
mcgl
pneumonia
mcgl
tend
decreas
increas
clinic
sever
statist
signific
author
manuscript
author
manuscript
data
show
sever
viral
infect
lung
transplant
critic
factor
determin
whether
viral
isol
signific
effect
upon
lung
allograft
lung
transplant
recipi
viral
pneumonia
symptom
plu
posit
radiograph
like
progress
clad
graft
loss
symptomat
asymptomat
viral
infect
demonstr
effect
also
found
adenoviru
parainfluenza
coxsackieechovirus
independ
associ
subsequ
develop
clad
case
adenoviru
graft
loss
well
find
tendenc
toward
particular
clad
phenotyp
find
support
retrospect
studi
khalifah
show
increas
risk
bo
death
death
bo
follow
carv
infect
lower
respiratori
tract
carv
infect
defin
similarli
symptomat
cohort
correl
greatest
risk
bo
death
studi
limit
howev
patient
total
carv
infect
lower
tract
infect
posit
radiograph
four
develop
bo
prior
carv
infect
furthermor
use
immunofluoresc
viral
cultur
detect
viru
reduc
sensit
limit
detect
rsv
parainfluenza
influenza
adenoviru
lower
sensit
may
bias
sampl
toward
patient
higher
viral
burden
sever
infect
group
shown
herein
elev
risk
poor
outcom
prospect
studi
carv
identifi
multiplex
pcr
bal
lung
transplant
recipi
found
carv
infect
declin
month
frequent
carv
infect
versu
without
studi
assess
bo
primari
outcom
signific
differ
symptomat
person
asymptomat
patient
person
like
due
restrict
definit
symptomat
patient
cough
coryza
myalgia
sore
throat
fever
day
bal
may
led
misclassif
patient
studi
miss
symptomat
patient
use
definit
herein
recent
singlecent
studi
lung
transplant
recipi
develop
clad
also
found
carv
associ
subsequ
clad
recent
studi
carv
identif
reli
upon
techniqu
similar
case
carv
stratifi
accord
clinic
sever
import
present
studi
quantifi
risk
develop
clad
graft
loss
base
sever
clinic
present
may
help
guid
treatment
decis
patient
counsel
kumar
et
al
patient
initi
without
lower
respiratori
tract
symptom
progress
lower
respiratori
tract
diseas
progress
either
influenza
parainfluenza
virus
data
argu
nonpneumonia
carv
infect
neg
impact
clad
onset
graft
surviv
clinic
import
contemporari
use
highsensit
nucleic
acid
amplif
test
detect
virus
lower
potenti
clinic
insignific
number
although
specif
antivir
medic
avail
limit
number
carv
decis
administ
adjunct
therapi
inhal
ribavirin
complic
issu
cost
physic
isol
patient
potenti
aggrav
respiratori
symptom
concern
teratogen
among
healthcar
personnel
find
infect
caus
adenoviru
parainfluenza
viru
like
progress
clad
probabl
virus
often
associ
viral
pneumonia
encount
abl
statist
demonstr
coxsackieechoviru
group
suspect
associ
clad
driven
subpopul
virus
detect
pcr
reaction
therebi
diminish
abil
see
associ
viral
pneumonia
viral
group
prior
studi
emphas
least
human
rhinovirus
lower
respiratori
tract
diseas
associ
higher
viral
load
may
pcronli
group
virus
categor
coxsacki
echoviru
contain
larg
number
hrv
repres
hrv
infect
higher
viral
load
lower
respiratori
tract
diseas
rsv
independ
risk
clad
studi
independ
associ
bo
numer
prepcr
era
studi
suspect
due
unavoid
bia
earlier
studi
reli
upon
passiv
case
detect
limit
carv
identif
sicker
patient
use
less
sensit
nonpcr
base
method
paramyxovirus
like
identifi
appear
even
mild
diseas
carv
deleteri
effect
lung
function
recent
prospect
studi
lung
transplant
recipi
found
mean
transitori
loss
ml
compar
preinfect
lung
function
test
yet
mechan
viral
pneumonia
increas
risk
clad
graft
loss
entir
understood
studi
directli
address
issu
case
viral
pneumonia
may
evolv
acut
lung
injuri
diffus
alveolar
damag
diffus
alveolar
damag
increas
subsequ
risk
clad
death
lung
transplant
perhap
via
chemokin
axi
weigt
et
al
also
demonstr
increas
ligand
concentr
bal
carv
infect
predict
declin
month
although
studi
suggest
potenti
mechan
carv
pneumonia
lead
clad
studi
lung
allograft
inflammatori
state
carv
necessari
better
elucid
respons
pathway
describ
largest
cohort
yet
pseudomona
isol
lung
transplant
find
respiratori
pseudomona
isol
elev
risk
clad
graft
loss
import
clad
determin
graft
loss
note
highlight
need
novel
effect
intervent
prevent
treat
clad
order
improv
surviv
lung
transplant
studi
advantag
largest
cohort
publish
date
address
effect
commun
viral
infect
clad
onset
graft
loss
lung
transplant
knowledg
year
followup
data
longest
observ
period
monitor
advers
outcom
lung
allograft
respect
carv
effect
viral
isol
upon
transplant
outcom
therefor
limit
event
within
first
year
transplant
span
entir
posttranspl
followup
period
studi
limit
includ
retrospect
singlecent
natur
studi
inher
risk
bia
minim
use
multivari
analysi
multiplex
pcr
introduc
laboratori
octob
year
studi
time
period
although
impact
assess
outcom
hypothes
reason
introduct
impact
model
signific
viral
infect
caus
influenza
parainfluenza
enteroviru
rsv
adenoviru
alreadi
identifi
adequ
prior
introduct
pcr
test
suspect
rel
low
rate
influenza
infect
explain
part
high
rate
influenza
vaccin
cohort
preemptiv
therapi
oseltamivir
peak
season
anoth
limit
includ
difficulti
diagnos
viral
pneumonia
immunocompromis
patient
may
subtl
imag
find
easili
seen
chest
radiograph
patient
studi
ct
scan
time
carv
diagnosi
may
result
underestim
total
number
patient
pneumonia
irregular
pft
followup
time
carv
episod
cohort
allow
us
determin
greatest
time
period
risk
clad
follow
carv
without
introduc
signific
bia
model
furthermor
posit
data
carv
episod
littl
neg
data
comment
upon
durat
viral
exposur
bacteri
coinfect
shortli
carv
may
contribut
graft
loss
clad
howev
observ
case
concurr
viral
bacteri
infect
state
data
set
defin
within
day
anoth
given
small
sampl
size
underpow
detect
expect
effect
result
lend
credenc
clinic
assess
argu
posit
test
attent
treatment
focu
evid
symptomat
diseas
rather
incident
posit
specimen
sinc
outcom
depend
infect
sever
perhap
viru
type
propos
futur
studi
evalu
impact
carv
infect
lung
allograft
stratifi
infect
sever
viru
type
frequenc
commun
acquir
viru
episod
month
season
patient
transplant
januari
juli
larger
dot
repres
greater
number
episod
smaller
dot
number
episod
given
dot
number
whose
size
also
correl
number
episod
multivari
cox
proport
hazard
model
clad
onset
covari
signific
p
univari
analysi
timedepend
viral
infect
base
clinic
sever
mutual
exclus
model
patient
retain
highest
level
sever
date
refer
condit
neg
viral
infect
abbrevi
ar
acut
reject
ci
confid
interv
clad
chronic
lung
allograft
dysfunct
ipf
idiopath
pulmonari
fibrosi
tabl
baselin
characterist
tabl
transplant
outcom
